Fifty-six patients with chemosensitive NHL were studied to assess factors affecting mobilization and peripheral blood stem cell (PBSC) collection: all were mobilized with high-dose cyclophosphamide and etoposide and G-CSF 5 g/kg/day. None of them had bone marrow involvement at the time of mobilization or a history of extended field irradiation. Previous chemotherapy regimens were divided into two groups: moderately myelotoxic chemotherapy (MMC) and highly myelotoxic chemotherapy (HMC). The adequacy of the PBSC harvest was not associated with age, gender, a past history of bone marrow involvement or disease status. In contrast, the number of MMC cycles (n (MMC) ) and the number of HMC cycles (n (HMC) ) were both significant (P = 0.009 and P = 0.0004, respectively) and were used to compute a score predictive of a successful PBSC harvest: SCORE = n . The estimated successful PBSC collection rate was greater than 80% in patients with a score ranging from 0 to 15 and dropped rapidly to below 20% in patients with a score exceeding 25. This scoring system may help to determine the timing of PBSC mobilization in patients with a score below 15 and suggests that new PBSC mobilization procedures should be investigated in other patients. Bone Marrow Transplantation (2000) 25, 495-499. 
Some patients with poor prognosis lymphoma can now be cured with high-dose chemotherapy followed by hematological stem cell support 1, 2 and peripheral blood stem cells (PBSC) accelerate hematological recovery at a faster rate than bone marrow stem cells. 3 Consequently, the surgical bone marrow harvest procedure has progressively been replaced by peripheral blood collection obtained by leukapheresis. Although PBSC mobilization and collection techniques have improved, the yield is still suboptimal in a subset of patients. In particular, heavily pretreated patients are thought to be at high risk for poor PBSC collection. 4 Achieving a complete remission (CR) before stem cell transplantation is one of the most important prognostic factors for subsequent disease-free survival. In this regard, various pre-transplantation regimens have been widely used either as front-line therapy 2, 5, 6 or as salvage regimens. 1, 7 Dose escalation strategies are easily managed with granulocyte colony-stimulating factor (G-CSF) that attenuate chemotherapy-induced neutropenia resulting from myelosuppression. If encouraging results have been reported in terms of response rates, few data are available concerning the toxicity such treatments inflict on stem cells. It has been hypothesized that the increased and repeated neutropenia and thrombocytopenia inevitably associated with such strategies may lead to bone marrow exhaustion and thus limit the feasibility of PBSC mobilization.
To address this question, we retrospectively reviewed a homogeneous group of 56 patients with non-Hodgkin's lymphoma in whom a PBSC harvest was attempted, and established a scoring system assessing previous chemotherapy capable of predicting the chances of a successful PBSC harvest.
Patients and method

Eligibility criteria
This study included all the patients with a diagnosis of NHL -whatever the histologic subtype -who were seen in our institution from January 1995 to October 1998 for a first attempt at PBSC mobilization. The other eligibility criteria were (1) mobilization with the same chemotherapy regimen: cyclophosphamide (1500 mg/m 2 × 3 on day 1) and etoposide (150 mg/m 2 × 3 on day 1) followed by granulocyte colony-stimulating factor (5 g/kg/day) (ETO/CY/G-CSF) and (2) a CR (or a major partial response) status with normal bone marrow histology before mobilization.
Patients in first remission (partial or complete) were eligible for PBSC mobilization if they had bulky low-grade lymphoma initially 8, 9 or, in cases of aggressive NHL, if they had two or three risk factors of the international index. 10 All patients in second or subsequent remission were eligible for transplantation.
The following subjects were excluded: patients older than 60 years, patients with PS Ͼ 1, inadequate bone marrow function (leukocyte count Ͻ3 × 10 9 /l and platelet count Ͻ100 × 10 9 /l), a previous history of extended field radiation (mantle, lumbar-aortic or pelvic) or of autologous stem cell transplantation.
Past history of chemotherapy
The various chemotherapy regimens were recorded and classified as either highly myelotoxic (у75% of grade 4 hematological toxicity) or moderately myelotoxic (Ͻ75% of grade 4 hematological toxicity according to the WHO classification). 'Super-CHOP' and cytarabine-based regimens (see below) were classified as highly myelotoxic regimens (HMC); whereas prednimustine, fludarabine, COP or CHOP-like regimens were classified as moderately myelotoxic chemotherapy (MMC). Prophylactic G-CSF was extensively prescribed after HMC.
Low-grade lymphoma:
First-line therapy included prednimustine, fludarabine monophosphate, COP (cyclophosphamide, vincristine and prednisolone), and 'CHOP-like' regimens: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone); CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone); CHVMP-VB 11 (cyclophosphamide, doxorubicin, teniposide, bleomycin and prednisolone); m-CHVMP 8 (cyclophosphamide, doxorubicin, teniposide, prednisolone and interferon-␣).
Second-line treatment included DHAP 1 (cisplatinum, cytosine arabinoside and dexamethasone); MAMI 12 (mitoguazone, amsacrine, cytosine and ifosfamide) and ETO/CY (etoposide 450 mg/m 2 and cyclophosphamide 4500 mg/m 2 ).
Aggressive lymphoma: First-line therapy consisted of 'CHOP-like' regimens or 'Super-CHOP' regimens: ACVBP 13 (doxorubicin, cyclophosphamide, vindesine and prednisone); ECVBP 14 (epirubicin, cyclophosphamide, vindesine, bleomycin and prednisone). Consolidation therapy included the IVAM regimen 15 (ifosfamide, etoposide, cytosine arabinoside and methotrexate), intermediate-dose methotrexate, ifosfamide + etoposide regimen and low-dose subcutaneous cytarabine. 6 Second-line therapy included DHAP, MAMI, ETO/CY as previously described.
Leukapheresis
At the end of aplasia, the CD34 + cell count was monitored daily in a morning peripheral blood sample by flow cytometry. Leukaphereses were not performed if blood CD34 + cell levels had not attained 20 × 10 3 /ml. Leukaphereses were achieved with a continuous-flow blood cell separator COBE Spectra (COBE Laboratories Ltd, Gloucester, UK). The total volume processed in each leukapheresis was two blood volumes at a flow rate of 40-60 ml/minute. The CD34 + cell count was verified in each daily leukapheresis product. The PBSC collection was considered successful if the CD34 cell yield exceeded 2.5 × 10 6 cells/kg in one to three leukapharesis.
Data analysis
Chi-square tests (categorical prognostic variables) or Wilcoxon rank order tests (continuous prognostic variables) were used to test the associations between the outcome of the PBSC collection and prognostic factors. The potential prognostic factors were introduced in a stepwise logistic regression model. The relationship between the prognostic parameters and the probability of harvesting failure was calculated using logistic regression results. 16 The relationship between the prognostic parameters and the probability of harvest failure was calculated using a linear logistic regression model. If x is the vector of explanatory variables, and p, the probability of harvest failure, the linear logistic regression model has the form logit(p) = log(p/(1 − p)) = ␣ + ␤ x, where ␣ is the intercept parameter and ␤ the vector of slope parameters. The estimation of ␣ and of the ␤s allows the computation of a score proportional to logit(p). All computations were performed using the SAS/STAT Software.
Results
Patient characteristics (Table 1)
The median age was 48 years (range 24-60). There were 32 men and 24 women. Twenty-four patients (43%) were in first remission (partial n = 15, complete n = 9) and 32 (57%) in second or subsequent remission (partial n = 9, complete n = 23). Twenty-seven (48%) patients had a history of bone marrow involvement but none of them had histological evidence of bone marrow involvement at the time of PBSC mobilization.
According to the REAL classification, 17 24 patients had diffuse large cell lymphoma, 24 follicular lymphoma, five mantle zone lymphoma and three small cell lymphocytic lymphoma. The mean time interval (MTI) between the initial diagnosis and the start of the mobilization regimen (priming) was 13 months (range 5-86). The time interval between the completion of the last cycle of chemotherapy and the date of priming ranged from 4 to 5 weeks.
PBSC were successfully mobilized in 40 patients (71%). The median yield of CD34 + cells was 4 × 10 6 CD34 + cells/kg (range 2.5-33). All the patients who subsequently underwent PBSC transplantation benefited from a sustained hematological recovery: median neutrophil recovery (Ͼ0.5 × 10 9 /l) was 11 (range 9-13) and median platelet recovery (Ͼ50 × 10 9 /l) was 13 (range 9-33).
Previous chemotherapy
One hundred and seventeen HMC cycles (37 Super CHOP, 20 ETO/CY and 60 cytarabine-based regimen) and 409 MMC cycles (288 CHOP-like, 83 COP or prednimustine, 20 fludarabine and 18 others) were evaluated.
Patient characteristics and CD34 + cell yield
In the univariate analysis, successful PBSC collection was associated with a small number of chemotherapy cycles (the mean at 8.5 in successful patients vs 11.8 in patients who failed; P = 0.04) and a small number of HMC cycles (mean, 1.5 vs 3.7; P = 0.002). None of the other factors studied (age, gender, complete or partial remission, first or subsequent remission, a history of bone marrow involvement, the histologic type of lymphoma and the mean time interval between diagnosis and priming) were significantly associated with successful PBSC collection ( Table 2 ). In the multivariate logistic regression model, the number of MMC cycles (n (MMC) ) and the number of HMC cycles (n (HMC) ) administered before the mobilization regimen were both significant (P = 0.009 and P = 0.0004, respectively). Table 2 Relationship between patient characteristics and CD34 + cell yield -univariate analysis
Characteristics
Peripheral blood progenitor harvest P у2. 1.5 (0-5) 3.7 (0-9) 0.002 HMC = highly myelotoxic regimen.
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The model parameter corresponding to HMC (␤HMC) was four times larger than the model parameter corresponding to MMC (␤MMC). Therefore, the probability of harvest failure was computed as a function of the score: SCORE = n (MMC) + 4n (HMC) , where each cycle of HMC counts as four cycles of MMC. The estimated successful PBSC collection rates exceeded 80% in patients with a score ranging from 0 to 15 and were below 20% in patients with a score greater than 25 ( Figure 1 ). This scoring system allowed three groups to be defined, one with a low (score 0-15), one with an intermediate (score [16] [17] [18] [19] [20] [21] [22] [23] [24] and the other with a high (score Ͼ25) probability of unsuccessful PBSC harvest.
Of the 56 patients, 31 were in the low risk group, 18 in the intermediate group and seven in the high risk group with successful PBSC collection rates of 93%, 61% and 0%, respectively.
Discussion
Several reports have sought to define parameters associated with a successful PBSC harvest, and factors such as previous chemotherapy, 4, 18, 19, 20 age, 18 and the mobilization procedure 21 were singled out as relevant. A history of extended field radiotherapy was, as expected, also found to profoundly and constantly affect PBSC collection. 4, 18, 19, 20 These studies were, however, conducted in heterogeneous populations with various hematological malignancies as well as solid tumors, and differences in their response status (complete response or persistent disease).
We analyzed a set of parameters that are readily available when intensification is planned for NHL patients. We chose a simple distinction between the various protocols based on the extent to which they induce grade 4 hematological toxicity. This distinction was not only for practical reasons but because repeated high-dose chemotherapy with the support of hematopoietic growth factors (HGF) leads to higher cumulative hematological toxicity, not only via direct toxicity but also through depletion of the bone marrow reserve due to repeated recruitment of stem cells by HGF. This assumption is supported by results obtained in animal models 22, 23 and by recent clinical data. 5, 24 In our study the number of MMC and HMC cycles were both associated with the probability of adequate PBSC collection. Since most of our patients receive both types of regimen at different periods of their disease, we felt that the respective impact required assessment. We established a score which allocated a four-fold greater value to HMC than to MMC.
The patient group under study is relatively small. Consequently, our scoring system may be center-specific to some degree. However, the procedure of mobilization is widely accepted and the distinction between myelotoxic and nonmyelotoxic regimen is easily transposable.
Nevertheless, our score may help to tailor general strategies to fit each patient by taking into account past as well as future chemotherapy regimens when PBSC collection and high-dose chemotherapy are planned. Thus, for a patient with a relapsing aggressive NHL after initial standard therapy or after a dose-escalated front-line regimen, PBSC mobilization can be considered after two to three cycles of salvage therapy in the first case, or should be attempted without delay in the second case.
The score may also prompt reflection about alternative procedures for stem cell collection. Most of the patients in the low risk group (score р15) are successfully mobilized but alternative procedures should be considered for those in the intermediate or high risk group (score Ͼ15). In this respect the addition of stem cell factor to G-CSF in a frontline mobilization procedure may be a viable option rather than harvesting autologous bone marrow. 25, 26 
